Clinical trials: Dupilumab
Dermatitis, Atopic
NMF-CsA-Dupi Trial
The goal of this study is to investigate whether stratification of children with atopic dermatitis on the NMF biomarkers results in an improvement of effectiveness and efficiency in the use of systemic treatment (ciclosporin and…
- Trial name
- NCT04878770
- Testing
- Topical corticosteroids, Systemic cyclosporine, Systemic dupilumab
- Where
- Netherlands
- Volunteers
- 318 people
- Sponsor
- Erasmus Medical Center
Chronic Rhinosinusitis With Nasal Polyps
BIOlogics in Severe Nasal POlyposis SurvEy
With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life.
- Trial name
- BIOPOSE (NCT05228041)
- Testing
- Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Atopic Dermatitis
ADBest TREAT Registry
Atopic dermatitis is a chronic inflammatory skin disease associated with intense pruritus, recurrent eczematous lesions, sleep disturbance, and reduced quality of life.
- Trial name
- ADBest-TREAT (NCT07904546)
- Testing
- Abrocitinib, Baricitinib, Upadacitinib
- Where
- Germany
- Volunteers
- 5,000 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately…
- Trial name
- NCT05049122
- Testing
- Dupilumab SAR231893
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Sanofi
Coronavirus Infection
Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy
This study will assess the prevalence and incidence of COVID-19 infection in patients with chronic plaque psoriasis on immunosuppressant therapy.
- Trial name
- NCT04324866
- Testing
- Nasopharyngeal swab
- Volunteers
- 300 people
- Sponsor
- Universita di Verona
Chronic Obstructive Pulmonary Disease
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by Annualized rate of acute moderate or severe COPD…
- Trial name
- NOTUS (NCT04456673)
- Testing
- Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist
- Where
- 334 sites in United States, Argentina and 27 more
- Volunteers
- 935 people
- Sponsor
- Sanofi
Atopic Dermatitis
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.
- Trial name
- CKD-706 (NCT07358156)
- Testing
- CKD-706, US-Dupixent, EU-Dupixent
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Eczema, Atopic Dermatitis
Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"
- Trial name
- NCT05265234
- Testing
- Dupilumab, Optical Coherence Tomography, Reflectance confocal microscopy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OptiSkin Medical
Atopic Dermatitis
Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
'Mind and Skin': A prospective cohort study evaluating the impact of inflammation, itch and sleep disturbance on the brain, mental health and cognition, in patients with severe atopy.
- Trial name
- NCT05790330
- Testing
- Methotrexate, Dupilumab
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- King's College London
Atopic Dermatitis
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"
Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT04033367
- Testing
- Dupilumab
- Where
- 42 sites in United States, Australia and 8 more
- Volunteers
- 188 people
- Sponsor
- Sanofi
Atopic Dermatitis
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD)…
- Trial name
- CHRONOS (NCT02260986)
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 148 sites in United States, Australia and 12 more
- Volunteers
- 740 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly…
- Trial name
- CRSwNP (NCT05246267)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Montefiore Medical Center
Breast Cancer
PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer
This proposal is for a Window of Opportunity (WOO) clinical trial using a novel combination of two Health Canada approved agents, cemiplimab (Libtayo) and dupilumab (Dupixent), for off label use in early-stage estrogen receptor…
- Trial name
- NCT05967884
- Testing
- Arm A: Cemiplimab, Arm B: Cemiplimab + Dupilumab
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Eosinophilic Esophagitis
Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
The goal of this clinical trial is to [primary purpose: e.g., learn if intervention or health behavior can treat, prevent, diagnose etc.] in [describe participant population/primary condition; could include any of the following…
- Trial name
- DeTECTS (NCT06705387)
- Testing
- Dupilumab, Fluticasone
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- University of Colorado, Denver
Healthy Volunteers
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
This is a Phase 1 study with 2 parallel groups of healthy participants. Participants will be randomized to receive either a subcutaneous (SC) dose of dupilumab coformulated with berahyaluronidase alfa or a SC dose of dupilumab…
- Trial name
- NCT07646548
- Testing
- Dupilumab coformulated with berahyaluronidase alfa, Dupilumab
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi
Keloid
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
The study investigates the efficacy and safety of dupilumab in the treatment of keloids
- Trial name
- NCT05128383
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center
Nasal Polyps, Asthma, Aspirin-Induced
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease
The overall aim of the study is to determine the clinical efficacy and mechanisms of action of anti-IL-4a (dupilumab) as treatment for patients with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) and Aspirin-Exacerbated…
- Conditions
- Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
- Trial name
- MARINER (NCT05575037)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Brigham and Women's Hospital
Allergic Rhinoconjunctivitis, Grass Pollen Allergy
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
The primary objective of this study is to assess whether the combination of grass allergen sublingual immunotherapy (SLIT) and dupilumab for 2 years is more effective than double placebo in suppressing the nasal allergen…
- Trial name
- GRADUATE (NCT04502966)
- Testing
- Dupixent®, Grazax®
- Where
- United Kingdom
- Volunteers
- 199 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Evaluation of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis
Primary Objective: To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT03912259
- Testing
- Dupilumab, Emollient (moisturizer)
- Where
- 27 sites in China
- Volunteers
- 165 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Tapering of Biologics in Chronic Rhinosinusitis With Nasal Polyps
The purpose of this study is to investigate the feasibility of extending the dosing intervals of biological therapies while maintaining optimal treatment effects in chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- NCT07187583
- Testing
- increased dosing interval of biological therapy
- Where
- 9 sites in Denmark
- Volunteers
- 135 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet